MIR539

Summary

MIR539 (microRNA 539, HGNC:32529) is a microRNA gene on chromosome 14q32.31.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 664612 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32529
Approved symbol	MIR539
Name	microRNA 539
Location	14q32.31
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-539
Ensembl gene	ENSG00000202560
Ensembl biotype	miRNA
Entrez	664612
RNAcentral	URS0000759CA5 — miRNA, 78 nt, 15 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000365690

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000365690 — 1 exons

Exon	Start	End
ENSE00001440453	101047321	101047398

Expression profiles

Bgee: expression breadth broad, 59 present calls, max score 94.82.

Top tissues by expression

59 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	94.82	gold quality
colon	UBERON:0001155	83.66	gold quality
stomach	UBERON:0000945	81.10	gold quality
lung	UBERON:0002048	78.12	gold quality
placenta	UBERON:0001987	77.47	gold quality
kidney	UBERON:0002113	77.29	gold quality
liver	UBERON:0002107	76.60	gold quality
intestine	UBERON:0000160	75.23	gold quality
muscle of leg	UBERON:0001383	74.06	gold quality
adrenal gland	UBERON:0002369	73.96	gold quality
heart	UBERON:0000948	73.72	gold quality
blood	UBERON:0000178	72.14	gold quality
substantia nigra	UBERON:0002038	71.31	gold quality
midbrain	UBERON:0001891	71.30	gold quality
body of pancreas	UBERON:0001150	70.44	gold quality
body of stomach	UBERON:0001161	70.03	gold quality
gastrocnemius	UBERON:0001388	69.95	gold quality
muscle layer of sigmoid colon	UBERON:0035805	69.04	gold quality
endometrium	UBERON:0001295	68.44	gold quality
skin of abdomen	UBERON:0001416	68.35	gold quality
left ovary	UBERON:0002119	67.83	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	67.53	gold quality
ovary	UBERON:0000992	67.31	gold quality
left adrenal gland cortex	UBERON:0035825	67.23	gold quality
lower esophagus muscularis layer	UBERON:0035833	66.94	gold quality
tibial artery	UBERON:0007610	66.67	gold quality
left adrenal gland	UBERON:0001234	66.55	gold quality
right adrenal gland cortex	UBERON:0035827	66.36	gold quality
hypothalamus	UBERON:0001898	66.29	gold quality
putamen	UBERON:0001874	65.74	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.16

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• The results of this study suggest that miR-539 is among the factors sensing biotin and regulating holocarboxylase synthetase expression. (PMID:20592104)
• This work identifies the first target of miR-539 in the heart and the first miRNA that regulates OGA. (PMID:25183011)
• Taken together, our data indicate that miR-539 is a novel regulator of migration and invasion in human thyroid cancer cells by targeting CARMA1. (PMID:26206083)
• miR-539 plays a key role in inhibiting osteosarcoma cell invasion and migration and can regulate MMP8 expression in osteosarcoma cells. (PMID:26339374)
• miR-539 plays an important role in the initiation and progression of nasopharyngeal carcinoma by targeting CDK4. (PMID:26559153)
• Results showed a progression-driving role of SPAG5 in prostate cancer which can be regulated by miR-539. (PMID:27037000)
• miR-539 functions as a tumor suppressor in hepatocellular carcinoma and reexpression of this miRNA offers a potential therapeutic strategy for this disease. (PMID:27717846)
• our results demonstrate that AR can promote melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signal and targeting this newly identified signal with AR degradation enhancer ASC-J9 may help us to better suppress the melanoma metastasis. (PMID:27869170)
• RESULTS: The results of our experiments demonstrated an increase in the expression of miR-539 and a decrease in the expression of MEK. Furthermore, we observed that miR-539 inhibited the expression of MEK through targeting of the 3’UTR of MEK; this led not only to suppressed proliferation but also to apoptosis and autophagy of H9C2 cells. (PMID:27981363)
• LOC100129148 enhanced KLF12 expression through functioning as a competitive ‘sponge’ for miR-539-5p in nasopharyngeal carcinoma (PMID:28328537)
• MiR-539 is down-regulated in hepatocellular carcinoma.MiR-539 inhibits FSCN1 expression and suppresses hepatocellular carcinoma migration and invasion. (PMID:28393215)
• These findings suggest that the manipulation of miR-539-5p/CXCR7 levels may have important therapeutic implications in choroidal neovascularization-associated diseases (PMID:29146732)
• miR-539 functions as a tumor suppressor in breast cancer by down-regulating EGFR. (PMID:29391441)
• miR-539 acted as a tumor suppressor in RCC cells by suppressing cell proliferation and inducing cell apoptosis, and this suppression may be due, at least in part, to the modulation of HMGA2 through the AKT signaling pathway. (PMID:29436648)
• miR539 may inhibit the aggressive behaviour of PDAC by directly targeting IGF1R and may serve as a novel therapeutic target for patients with this disease (PMID:29901181)
• MiR-539 is down-regulated in the hepatocellular carcinoma. MiR-539 targets MAP2K1 and regulates ERK1/2/c-Jun pathway the hepatocellular carcinoma. (PMID:30217449)
• miR-539 was downregulated in WT tissues. And miR-539 inhibited the progression of WT through negatively regulating JAG1-Notch1/3 expression. MiR-539 should be a valuable indicator of the diagnosis and prognosis of WT. (PMID:30530967)
• MiR-539-3p promotes the progression of epithelial ovarian cancer by targeting SPARCL1. (PMID:30964161)
• The results of the current study present evidence emphasizing the significance of the interactions between miR-539 and TWIST1 in the development of and progression of PC. (PMID:31022384)
• MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-beta/Smad4 signalling pathway by down-regulating DLX1. (PMID:31298493)
• The results revealed low expression of miR539 and high expression of SOX5 in gastric cancer tissues and cells as compared with the levels in normal tissues and cells, suggesting that there was a negative correlation between miR539 and SOX5. (PMID:31322222)
• Low miR539 expression is associated with gastric cancer. (PMID:31403943)
• MiR-539 inhibits the malignant behavior of breast cancer cells by targeting SP1. (PMID:31742423)
• LncRNA LUCAT1 contributes to cell proliferation and migration in human pancreatic ductal adenocarcinoma via sponging miR-539. (PMID:31789465)
• LncRNA-ZNF281 Interacts with miR-539 to Promote Hepatocellular Carcinoma Cell Invasion and Migration. (PMID:32073896)
• miR539 suppresses the proliferation, migration, invasion and epithelial mesenchymal transition of pancreatic cancer cells through targeting SP1. (PMID:32236568)
• lncRNA CRNDE promotes the proliferation and metastasis by acting as sponge miR-539-5p to regulate POU2F1 expression in HCC. (PMID:32252678)
• MiR-539-5p Decreases amyloid beta-protein production, hyperphosphorylation of Tau and Memory Impairment by Regulating PI3K/Akt/GSK-3beta Pathways in APP/PS1 Double Transgenic Mice. (PMID:32415525)
• CASC21, a FOXP1 induced long non-coding RNA, promotes colorectal cancer growth by regulating CDK6. (PMID:32584787)
• LINC00460 promotes proliferation and inhibits apoptosis of non-small cell lung cancer cells through targeted regulation of miR-539. (PMID:32633366)
• A SNP-mediated lncRNA (LOC146880) and microRNA (miR-539-5p) interaction and its potential impact on the NSCLC risk. (PMID:32795333)
• LncRNA TP73-AS1/miR-539/MMP-8 axis modulates M2 macrophage polarization in hepatocellular carcinoma via TGF-beta1 signaling. (PMID:32818670)
• Circ_0004104 Accelerates the Progression of Gastric Cancer by Regulating the miR-539-3p/RNF2 Axis. (PMID:33449226)
• LncRNA PCGEM1 contributes to malignant behaviors of glioma by regulating miR-539-5p/CDK6 axis. (PMID:33589577)
• Amniotic fluid microRNA profiles in twin-twin transfusion syndrome with and without severe recipient cardiomyopathy. (PMID:34153234)
• Recombinant water stress protein 1 (Re-WSP1) suppresses colon cancer cell growth through the miR-539/beta-catenin signaling pathway. (PMID:34596809)
• miR-539 Targeting SNAI2 Regulates MMP9 Signaling Pathway and Affects Blood-Brain Barrier Permeability in Cerebrovascular Occlusive Diseases: A Study Based on Head and Neck Ultrasound and CTA. (PMID:34873439)
• lncRNA LINC000466 Predicts the Prognosis and Promotes the Progression of Triple-negative Breast Cancer via Modulating miR-539-5p. (PMID:35216934)
• Regulation of Iron-Ion Transporter SLC11A2 by Three Identical miRNAs. (PMID:36047197)
• LncRNA TP73-AS1 enhances the malignant properties of colorectal cancer by increasing SPP-1 expression through miRNA-539-5p sponging. (PMID:36801509)

Cross-species orthologs

0 orthologs

Paralogs (16): MIR494 (ENSG00000194717), MIR377 (ENSG00000199015), MIR381 (ENSG00000199020), MIR369 (ENSG00000199025), MIR323A (ENSG00000199069), MIR410 (ENSG00000199092), MIR409 (ENSG00000199107), MIR487A (ENSG00000207742), MIR487B (ENSG00000207754), MIR656 (ENSG00000207959), MIR496 (ENSG00000207961), MIR154 (ENSG00000207978), MIR323B (ENSG00000208004), MIR1185-1 (ENSG00000221525), MIR1185-2 (ENSG00000221614), MIR382 (ENSG00000283170)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.